Biohaven Pharma (BHVN) Tops Q4 EPS by 28c

Biohaven Pharma (NYSE: BHVN) reported Q4 EPS of ($2.69), $0.28 better than the analyst estimate of ($2.97). Revenue for the quarter came in at $35.1 million versus the consensus estimate of $28.23 million.

For earnings history and earnings-related data on Biohaven Pharma (BHVN) click here.

You May Also Be Interested In

• Baird on Nurix (NRIX) Earnings Amid 7% Drop: '2Q Print Solid as Breadth of Development Expands'
• Occidental Petroleum releases Q2 2026 earnings considerations
• Financial Select Sector SPDR ETF (XLF) spreader of 20K contracts of July 31 weekly 57 and 59 calls into bank earnings season